Key facts
- This page summarizes Matthew L. Kaplan's Form 4 filing for Nuvectis Pharma, Inc. (NVCT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Jun 2026, 16:10.
Matthew L. Kaplan - 11 Jun 2026 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)
- Reporting relationship
- Director
- Issuer ticker
- NVCT
- Reported as of
- 11 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2026, 16:10:16 UTC
- Prior SEC filing
- 06 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Kaplan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Matthew L. Kaplan filed Form 4 for Nuvectis Pharma, Inc. (NVCT) on 12 Jun 2026.
Change
- Previous filing in this sequence was filed on 06 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001895952
Primary reporting owner
Kaplan Matthew L.
- Relationship
- Director
- Address
- C/O NUVECTIS PHARMA, INC.,, 1 BRIDGE PLAZA, SUITE 275, FORT LEE
- Signature
- /s/ Matthew Kaplan
- Signature date
- 12 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVCT
transaction
Common Stock
Award
- Transaction value
- Shares
- +35,000
- Change %
- +28%
- Price
- $0.000000*
- Shares after
- 159,760
- Date
- 11 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the Company's Board of Directors on such dates.
Footnote F2
Includes shares of restricted common stock.